<div id="readability-page-1"><div><h2>Medlive Technology FY 2025 earnings snapshot</h2> <p>Medlive Technology (SEHK:2192) has reported fresh numbers for FY 2025, with first half revenue of C¥312.0 million and basic EPS of C¥0.212. These figures help investors assess its current earnings power. The company’s revenue has moved from C¥243.4 million in the first half of 2024 to C¥315.0 million in the second half, and then to C¥312.0 million in the latest half. Over the same periods, basic EPS shifted from C¥0.202 to C¥0.230 and now C¥0.212. This provides a view of how both the top and bottom line have evolved across recent reporting periods. With trailing twelve month EPS at C¥0.456 and net income at C¥334.3 million, investor attention is likely to focus on how margins are reflected across these results.</p> <p>See our full analysis for Medlive Technology.</p><p>With the headline figures in place, the next step is to compare these results with the prevailing market narratives around Medlive Technology and evaluate which of those narratives remain relevant and which may be becoming outdated.</p> <p>Curious how numbers become stories that shape markets? Explore Community Narratives</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d63f4f7f-1164-45f3-8ef7-aa8d180ec75a/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTAzLTI3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d63f4f7f-1164-45f3-8ef7-aa8d180ec75a/chart/earnings-and-revenue-history/query-ZGF0ZT0yMDI2LTAzLTI3"/><figcaption>SEHK:2192 Earnings &amp; Revenue History as at Mar 2026</figcaption></figure> <h2>52.1% net margin points to high profitability</h2> <ul> <li>Over the last 12 months Medlive converted C¥334.3 million of net income from C¥642.2 million of revenue, which lines up with a 52.1% net margin compared with 56.4% in the prior year.</li> <li>Bulls often highlight the 37.5% per year earnings growth over five years, and the current 52.1% margin still supports that story. However, the most recent 6.1% one year earnings growth and the step down from a 56.4% margin show that profitability is not moving in a straight line.     <ul> <li>The trailing twelve month EPS of C¥0.456 is above each individual half year EPS in the table, which supports the bullish focus on earnings power, while the lower margin points to some pressure on how that profit is being earned.</li> <li>For a reader, this mix means the bullish angle of strong multi year growth is backed by solid margins. At the same time, the recent slowdown and margin shift are concrete data points that bulls need to factor in.</li> </ul> </li> </ul> <h2>P/E of 15.7x sits below industry</h2> <ul> <li>Medlive trades on a trailing P/E of 15.7x, which is below the Asian Healthcare Services industry average of 22.6x and below the peer average of 17.1x, with a DCF fair value of HK$8.31 compared with the current HK$8.05 share price.</li> <li>Supporters of a bullish stance argue that a lower P/E and a share price just under the HK$8.31 DCF fair value leave room for the market to re rate the stock. However, the recent 6.1% earnings growth rate compared with the 37.5% five year pace shows that slower growth could also be part of why the valuation is below peers.     <ul> <li>The combination of a 52.1% net margin and forecast earnings and revenue growth of around 11.2% and 19.3% a year is what bullish investors point to when they say the current P/E looks conservative.</li> <li>At the same time, critics can point to the one year growth slowdown and margin drift from 56.4% to 52.1% as reasons why the market is not paying industry level multiples yet.</li> </ul> </li> </ul><p> Curious how these valuation and margin signals fit into the broader story retail and professional investors are building around Medlive Technology right now? Curious how numbers become stories that shape markets? Explore Community Narratives. </p><h2>3.62% dividend brings cash flow questions</h2> <ul> <li>The stock offers a 3.62% dividend yield, and that payout is not well covered by free cash flow according to the latest twelve month figures.</li> <li>Bears focus on the combination of a 3.62% yield that lacks strong free cash flow backing and a margin move from 56.4% to 52.1%, arguing that these numbers make the payout look less robust even though earnings themselves have grown 6.1% over the last year.     <ul> <li>What stands out is that net income of C¥334.3 million is healthy on its own, but the cash coverage concern means shareholders are relying on continued strong operations to support the dividend.</li> <li>For cautious investors, this creates a clear tension between enjoying income today and keeping an eye on how free cash flow and margins evolve alongside the forecast 11.2% earnings growth.</li> </ul> </li> </ul> <h2>Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Medlive Technology's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.</p> <p>Mixed signals around earnings, margins, and the dividend can prompt very different views. Check the numbers yourself and balance both sides of the story by reviewing the 3 key rewards and 1 important warning sign.</p> <h2>Explore Alternatives</h2> <p>Medlive Technology combines a high 52.1% net margin with a 3.62% dividend that is not well covered by free cash flow and softer recent earnings growth.</p> <p>If that mix of cash flow pressure and payout uncertainty feels uncomfortable, you may want to focus on companies with stronger coverage by starting with the 470 dividend fortresses.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

02192

<p>Medlive Technology (SEHK:2192) reported FY 2025 earnings with a revenue of C¥312.0 million and basic EPS of C¥0.212. The company experienced a decline in net margin from 56.4% to 52.1%, raising concerns about profitability despite a trailing twelve month EPS of C¥0.456. The stock trades at a P/E of 15.7x, below industry averages, and offers a 3.62% dividend yield, which is not well supported by free cash flow. Investors are advised to consider long-term trends amidst mixed signals regarding earnings growth and margin stability.</p>

Medlive Technology (SEHK:2192) Net Margin Decline Challenges Longstanding Bullish Profitability Narratives